Company research
Metsera, Inc.
CIK 2040807Updated Sep 24, 2026
Filing activity
Latest filing
50 filings on record · SCHEDULE 13G/A, 15-12G, 4, SCHEDULE 13D/A, SCHEDULE 13G, S-8 POS.
About the company
We are a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Obesity and overweight are among the fastest-growing and most prevalent chronic human conditions, affecting approximately 2.5 billion people worldwide, and drive a broad range of severe diseases. Currently approved NuSH analog peptides are a promising treatment option for obesity and overweight. However, the current treatment landscape exhibits several key limitations, including impediments to chronic therapy in large populations, such as administration by weekly injection, prolonged titration and tolerability issues; insufficient weight loss; lack of effective, well-tolerated oral dosing alternatives; and challenges in scaling manufacturing. We have developed and are implementing proprietary methods and platform technologies that we believe will allow us to develop and advance a broad, scalable and combinable portfolio of injectable and oral NuSH analog peptides with the potential to not only address the limitations of approved therapies, but also many of the anticipated limitations o…
Recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 |
|---|---|---|
| ASSETS | ||
| AssetsUSD | 450,988,000Source | 168,841,000Source |
| Property, Plant and Equipment, NetUSD | 57,000Source | 27,000Source |
| GoodwillUSD | 21,892,000Source | 22,179,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 68,521,000Source | 69,421,000Source |
| Current assets: | ||
| Cash and Cash Equivalents, at Carrying ValueUSD | 352,400,000Source | — |
| Assets, CurrentUSD | 359,133,000Source | 76,804,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,686,000Source | 1,609,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,385,000Source | — |
| Other Assets, NoncurrentUSD | 0Source | 410,000Source |
| LIABILITIES AND EQUITY | ||
| LiabilitiesUSD | 163,638,000Source | 70,340,000Source |
| Stockholders’ equity: | ||
| Additional Paid in CapitalUSD | 2,479,000Source | 85,000Source |
| Retained Earnings (Accumulated Deficit)USD | -257,146,000Source | -48,019,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,160,000Source | 2,752,000Source |
| Stockholders' Equity Attributable to ParentUSD | -253,507,000Source | -45,182,000Source |
| Liabilities and EquityUSD | 450,988,000Source | 168,841,000Source |
| Current liabilities: | ||
| Liabilities, CurrentUSD | 67,307,000Source | 20,169,000Source |
| Operating Lease, Liability, CurrentUSD | 714,000Source | — |
| Accounts Payable, CurrentUSD | 20,837,000Source | 2,656,000Source |
| Operating Lease, Liability, NoncurrentUSD | 701,000Source | — |
| Deferred Income Tax Liabilities, NetUSD | 7,780,000Source | 17,261,000Source |
| Additional Financial Items | ||
| Deferred Tax Liabilities, NetUSD | 7,780,000Source | 17,261,000Source |
| Dividends Payable, CurrentUSD | — | 515,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -209,127,000Source | -47,206,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation, Depletion and AmortizationUSD | 14,000Source | 2,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,394,000Source | 85,000Source |
| Changes in operating assets and liabilities: | ||
| Increase (Decrease) in Accounts PayableUSD | 16,547,000Source | 2,601,000Source |
| Deferred Income Tax Expense (Benefit)USD | -9,338,000Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -100,039,000Source | -35,393,000Source |
| Cash flows from investing activities: | ||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 28,213,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -43,000Source | -28,242,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 43,000Source | 29,000Source |
| Cash flows from financing activities: | ||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 378,198,000Source | 123,683,000Source |
| Supplemental disclosure of cash flow information: | ||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 157,000Source | — |
| Additional Financial Items | ||
| Share-based Payment Arrangement, ExpenseUSD | 2,394,000Source | 85,000Source |
| Dividends Payable, CurrentUSD | — | 515,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 406,000Source | -3,000Source |
| General and Administrative ExpenseUSD | 26,797,000Source | 15,042,000Source |
| GoodwillUSD | 21,892,000Source | 22,179,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | -9,338,000Source | 0Source |
| InterestExpenseNonoperatingUSD | 223,000Source | — |
| Investment Income, InterestUSD | 6,185,000Source | 1,918,000Source |
| Net Income (Loss) Attributable to ParentUSD | -209,127,000Source | -47,206,000Source |
| Operating ExpensesUSD | 224,833,000Source | 43,669,000Source |
| Operating Lease, ExpenseUSD | 700,000Source | 400,000Source |
| Other Nonoperating Income (Expense)USD | 183,000Source | -5,455,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 |
|---|---|---|
| Operating Income (Loss)USD | -224,833,000Source | -43,669,000Source |
| Other Nonoperating Income (Expense)USD | 183,000Source | -5,455,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -218,465,000Source | -47,206,000Source |
| Income Tax Expense (Benefit)USD | -9,338,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -209,127,000Source | -47,206,000Source |
| Earnings Per Share, BasicUSD per share | -14.49Source | -3.48Source |
| Earnings Per Share, DilutedUSD per share | -14.49Source | -3.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 14,431,846Source | 13,571,987Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 14,431,846Source | 13,571,987Source |
| Interest Expense (non-operating)USD | 223,000Source | — |
| Additional Financial Items | ||
| Current Income Tax Expense (Benefit)USD | 0Source | 0Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 406,000Source | -3,000Source |
| General and Administrative ExpenseUSD | 26,797,000Source | 15,042,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -165,404,000Source | -45,681,000Source |
| Investment Income, InterestUSD | 6,185,000Source | 1,918,000Source |
| Operating ExpensesUSD | 224,833,000Source | 43,669,000Source |
| Operating Lease, ExpenseUSD | 700,000Source | 400,000Source |
| Research and Development ExpenseUSD | 107,517,000Source | 15,564,000Source |
Offerings
Registration 333-284225
- Gross proceeds
- 275000004.0
- Net proceeds
- 255750004.0
- Deal price
- 18.0
- Shares
- 15277778
- Offering price
- $18.00
- Ticker
- MTSR
Filing attachments
d900229dex107.htm · S-1 · 2025-01-10
EX-10.7 9 d900229dex107.htm EX-10.7 EX-10.7 Exhibit 10.7 1200 Morris Turnpike Suite 3005 Short Hills, NJ 07078 October 28, 2024 VIA E-MAIL [XXX] Christopher Visioli [XXX] [XXX] Dear Chris: On behalf of Metsera, Inc. (collectively with its subsidiaries and affiliates, the “Company”), we are pleased to extend you an offer of employment to become the Company’s Chief Financial Officer, pursuant to the terms of this offer letter (this “Letter”) which, if you accept, will govern…
Read attachment ↗d900229dex41.htm · S-1 · 2025-01-10
EX-4.1 5 d900229dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 NUMBER SHARES INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CUSIP XXXXXX XX X SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.00001 PAR VALUE PER SHARE, OF METSERA, INC. transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not v…
Read attachment ↗